Factors associated with long-term survival of patients with advanced non-small cell lung cancer

Respirology

Volumn 17, Issue 1, 2012, Pages 134-142

  Giroux Leprieur, Etienne ^a,b   Lavole, Armelle ^a   Ruppert, Anne Marie ^a   Gounant, Valérie ^a   Wislez, Marie ^a   Cadranel, Jacques ^a   Milleron, Bernard ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

advanced stage; long term survival; maintenance therapy; non small cell lung cancer

Indexed keywords

DOCETAXEL; ERLOTINIB; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; NAVELBINE; PEMETREXED; PLATINUM; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIFE EXPECTANCY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LIFE EXPECTANCY; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84255197409     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02070.x     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, et al,. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108. (Pubitemid 40372904)
2. Ihde DC,. Chemotherapy of lung cancer. N. Engl. J. Med. 1992; 327: 1434-41.
3. Scagliotti GV, Parikh P, von Pawel J, et al,. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 3543-51.
4. Sandler A, Gray R, Perry MC, et al,. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006; 355: 2542-50. (Pubitemid 44917502)
5. Satoh H, Ishikawa H, Yamashita YT, et al,. Analysis of long-term survivors after platinum containing chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 1998; 18: 1295-8. (Pubitemid 28234034)
6. Satoh H, Ishikawa H, Ohara G, et al,. Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 2007; 27: 4457-60.
7. Le Chevalier T, Brisgand D, Soria JC, et al,. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6 (Suppl. 1): 8-11. (Pubitemid 32155181)
8. Kojima A, Shinkai T, Eguchi K, et al,. Analysis of three-year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J. Clin. Oncol. 1991; 21: 276-81.
9. Caglayan B, Fidan A, Salepci B, et al,. Effects of prognostic factors and treatment on survival in advanced non-small cell lung cancer. Tuberk. Toraks 2004; 52: 323-32.
10. NSCLC Meta-analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systemic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 2008; 26: 4617-25.
11. D'Addario G, Pintilie M, Leighl NB, et al,. Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 2005; 23: 2926-36. (Pubitemid 46224111)
12. Ciuleanu T, Brodowicz T, Zielinski C, et al,. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-40.
13. Shepherd FA, Dancey J, Ramlau R, et al,. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000; 18: 2095-103. (Pubitemid 30324363)
14. Hanna N, Shepherd FA, Fossella FV, et al,. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-97. (Pubitemid 41079796)
15. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al,. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 123-32. (Pubitemid 41058344)
16. Massarelli E, Andre F, Liu DD, et al,. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39: 55-61. (Pubitemid 36020295)
17. Girard N, Jacoulet P, Gainet M, et al,. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J. Thorac. Oncol. 2009; 4: 1544-9.
18. Mountain CF,. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-17. (Pubitemid 27260107)
19. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 373-83. (Pubitemid 17055592)
20. Mountain CF, Dresler CM,. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 1718-23. (Pubitemid 27260108)
21. Miller AB, Hoogstraten B, Staquet M, et al,. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. (Pubitemid 11167383)
22. Weiss GJ, Rosell R, Fossella F, et al,. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2007; 18: 453-60. (Pubitemid 46359622)
23. Albain KS, Crowley JJ, LeBlanc M, et al,. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol. 1991; 9: 1618-26.
24. O'Connell JP, Kris MG, Gralla RJ, et al,. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J. Clin. Oncol. 1986; 4: 1604-14. (Pubitemid 17188927)
25. Stubbs M, McSheehy PM, Griffiths JR, et al,. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 2000; 6: 15-19. (Pubitemid 30010232)
26. Firth JD, Ebert BL, Ratcliffe PJ,. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem. 1995; 270: 21021-7.
27. Gronowitz JS, Bergstrom R, Nou E, et al,. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990; 66: 722-32. (Pubitemid 20281316)
28. Sculier JP, Paesmans M, Libert P, et al,. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. Eur. J. Cancer 1994; 30A: 1342-7. (Pubitemid 24322073)
29. Van Schil PE, Hendriks JM, Carp L, et al,. Surgery for oligometastatic disease in non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2008; 8: 1931-8.
30. Hotta K, Fujiwara Y, Matsuo K, et al,. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2009; 4: 311-17.
31. Johnson KR, Ringland C, Stokes BJ, et al,. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006; 7: 741-6. (Pubitemid 44283658)
32. Brodowicz T, Krzakowski M, Zwitter M, et al,. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63.
33. Cappuzzo F, Ciuleanu T, Stelmakh L, et al,. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-9.
34. Mok TS, Wu YL, Thongprasert S, et al,. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-57.
35. Eberhard DA, Johnson BE, Amler LC, et al,. Mutations in the epidermal growth factor receptor and in the KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005; 23: 5900-9.